Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 4, 2008, Pages 347-355

  De Groot, Philip G ^a   Derksen, Ronald H W M ^a   De Laat, Bas ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

Author keywords

2 glycoprotein I; Anticardiolipin antibodies; Antiphospholipid syndrome; Lupus anticoagulant

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; HUMAN; IMMUNOASSAY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; SEROLOGY; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC TESTS; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; REPRODUCIBILITY OF RESULTS; THROMBOSIS;

EID: 53049104863     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1085477     Document Type: Review

References (65)

1. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheumatol 1985;3:285-286
2. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-763
3. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interaction. Semin Hematol 1997;34:171-187
4. Reber G, Arvieux J, Comby E, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hémostase et la Thrombose). Thromb Haemost 1995;73:444-452
5. Wong R, Favaloro E, Pollock W, et al. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. Pathology 2004;36:182-192
6. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 1999;81:929-934
7. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995;74:1185-1190
8. Wong RC, Gillis D, Adelstein S, et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology 2004;36:63-68
9. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-1311
10. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
11. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4124
12. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-1547
13. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004;104:3598-3602
14. Haupt H, Schwick HG, Storiko K. On a hereditary beta-2-glycoprotein I deficiency. Humangenetik 1968;5:291-293
15. Sheng Y, Reddel SW, Herzog H, et al. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem 2001;276:13817-13821
16. 2-glycoprotein I only after a conformational change. Blood 2005;107:1916-1924
17. Kuwana M, Matsuura E, Kobayashi K, et al. Binding of {beta}2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005;105:1552-1557
18. Willems GM, Janssen MP, Pelsers MM, et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry 1996;35:13833-13842
19. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211-1214
20. McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989;73:506-513
21. Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992;1:75-81
22. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant / Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995;74:1185-1190
23. de Groot PG, Lutters B, Derksen RHWM, Lisman T, Meijers JCM, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005;3:1993-1997
24. Pengo V, Biasiolo A, Gresele P, et al. Participating Centres of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007;5:925-930
25. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-1832
26. Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A. Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb Res 2007;120:127-133
27. Favaloro EJ, Silverstrini R. Assessing the utility of anticardiolipin antibody assays: A cautious approach is suggested by high variation and limited consensus in multi-laboratory testing. Am J Clin Pathol 2002;118:548-557
28. Audrain MA, Colonna F, Morio F, Hamidou MA, Muller JY. Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1. Rheumatology (Oxford) 2004;43:181-185
29. Kutteh WH, Franklin RD. Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centres. Am J Obstet Gynecol 2004;191:440-448
30. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002;119:1005-1010
31. Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006;4:44-49
32. Bizzaro N, Ghirardello A, Zampieri S, et al. Antiprothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007;5:1158-1164
33. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147-1152
34. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007;110:1178-1183
35. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002
36. Neville C, Rauch J, Kassis J, et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003;90:108-115
37. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332-338
38. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006;33:2214-2221
39. Favaloro EJ, Wong RC, Jovanovich S, Robert-Thomson P. A review of beta-2-glycoprotein-I antibody testing results from a peer-driven multi-laboratory quality assurance program. Am J Clin Pathol 2007;127:441-448
40. Ichikawa K, Tsutsumi A, Atsumi T, et al. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis Rheum 1999;42:2461-2470
41. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005;3:1231-1238
42. Sailer T, Zoghlami C, Kurz C, et al. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost 2006;95:796-801
43. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004;63:1478-1482
44. De Laat B, Derksen RH, de Groot PG. High-avidity anti-beta glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta glycoprotein I antibodies. J Thromb Haemost 2006;4:1619-1621
45. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-632
46. Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-2625
47. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996;75:721-724
48. Cugno M, Cabibbe M, Galli M, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004;103:2121-2126
49. Bertolaccini ML, Mepani K, Sanna G, Hughes GR, Khamashta MA. Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis 2007;66:533-536
50. Bizzaro N, Ghirardello A, Zampieri S, et al. Antiprothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007;5:1158-1164
51. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997;337:154-160
52. Nakamura N, Kuragaki C, Shidara Y, Yamaji K, Wada Y. Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am J Hematol 1995;49:347-348
53. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007;109:1490-1494
54. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147-1152
55. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005;3:1160-1165
56. Ruffatti A, Tonello M, Del RT, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006;96:337-341
57. 2-glycoprotein I- and prothrombin- dependent lupus anticoagulants. J Thromb Haemost 2003;1:740-747
58. Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004;2:702-707
59. Devreese KM. A functional coagulation test to identify anti-beta2-glycoprotein I dependent lupus anticoagulants. Thromb Res 2007;119:753-759
60. De Laat B, Eckmann M, van Schagen M, Mertens K, van Mourik JA. Correlation between the potency of a beta2-glycoprotein I dependent lupus anticoagulant and the level of resistance to activated protein C [abstract P-S]. Presented at: XXIst Congress of the ISTH; July 6-12, 2007; Geneva, Switzerland
61. De Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of {beta}2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood 2005;105:1540-1545
62. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996;25:191-193
63. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007;56:2382-2391
64. Kasahara H, Matsuura E, Kaihara K, et al. Antigenic structures recognized by anti-beta2-glycoprotein I autoantibodies. Int Immunol 2005;17:1533-1542
65. Eschwège V, Darnige L, Piette JC, Boffa MC. European Forum on Antiphospholipid Antibodies: report on the first meeting, 10-11 October 1997, Hôpital Saint-Louis, Paris. Lupus 1998;7:439-444 356-360